Author

Alexander Spira

Observed name: A. Spira

Institution: Virginia Cancer Specialists

Observed institution: Virginia Cancer Specialists

ORCID: 0000-0003-1303-0447

Observed ORCID: 0000-0003-1303-0447

OpenAlex ID: A5037387706

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab

2025 · Zofia Piotrowska, Antonio Passaro, et al. · Journal of Clinical Oncology · 26

Abstract LB407: Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

2026 · Brian M. Wolpin, Benjamin L. Musher, et al. · Cancer Research · 13

8O First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4)

2025 · K. Cuppens, K. Papadopoulos, et al. · ESMO Open · 12

Abstract LB337: Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC)

2026 · Eileen M. O'Reilly, Brian Wolpin, et al. · Cancer Research · 7

502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors

2024 · D.S. Hong, K. Papadopoulos, et al. · European Journal of Cancer · 4

Abstract CT189: Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors

2026 · Rohit Thummalapalli, Ming Lu, et al. · Cancer Research · 1

Abstract CT048: A first in human, dose escalation (DE) and biomarker cohort expansion (BCE) of IMT-009 (IMT) in advanced cancer and Phase 1b (Ph1b) combination with fruquintinib (F) in microsatellite stable colorectal cancer (MSS CRC)

2026 · Susanna V. Ulahannan, Melissa Johnson, et al. · Cancer Research · 1

BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial

2026 · Michael S. Gordon, Richard D. Carvajal, et al. · Cancer Chemotherapy and Pharmacology · 1

195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors

2022 · I. Csiki, J. Glenn, et al. · Immuno-Oncology Technology · 1

Rinatabart sesutecan (Rina-S) plus bevacizumab (BEV) for patients (pts) with recurrent ovarian cancer (OC): First disclosure from cohort D2 of the phase 1/2 RAINFOL-01 study

2026 · Cara Mathews, Jessica Thomes Pepin, et al. · Gynecologic Oncology

Abstract CT092: A Phase 1a/1b, first-in-human study of an ADC targeting ADAM9 (DB-1317) in participants with selected advanced or metastatic solid tumors

2026 · Charlotte Lemech, Alexander Spira, et al. · Cancer Research

Abstract CT099: Phase 1/2a open-label clinical trial evaluating VBC101, an EGFR and cMET targeted bi-specific antibody drug conjugate (ADC), in participants with advanced solid tumormalignancies

2026 · Nehal Lakhani, David Sommerhalder, et al. · Cancer Research

Abstract CT193: Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial

2026 · Pedro Rocha, Manish Patel, et al. · Cancer Research

Abstract CT097: A Phase 1, first-in-human study of the SMARCA2 degrader, PLX-61639, in patients with SMARCA4-mutated, locally advanced or metastatic solid tumors

2026 · Jorge F. DiMartino, Alexander Spira, et al. · Cancer Research

Abstract CT002: First-in-human phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)

2026 · Timothy A. Yap, Andrae Vandross, et al. · Cancer Research

NAPISTAR 1-01: A Phase 1 dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate in patients with platinum-resistant high grade serous ovarian carcinoma.

2026 · Jalid Sehouli, Toon Van Gorp, et al. · International Journal of Gynecological Cancer

Works count: 16

Citation count: 66

H-index: 4

I10-index: 3